Scholarlink

Background <p>Ferroptosis, an iron-dependent form of regulated cell death, is crucial for the fate of tumors such as prostate cancer (PCa) under conditions of metabolic and oxidative stress. Consequently, the disruption of ferroptosis defense mechanisms could be lethal to these cancer cells, while sparing normal cells. Despite this potential, the development of effective and controlled in vivo therapies targeting ferroptosis remains underexplored.</p> Methods <p>In this study, liposomes modified with Glu-urea-Lys (GUL) encapsulating Mn<sub>0.6</sub>Zn<sub>0.4</sub>Fe<sub>2</sub>O<sub>4</sub> (MZ) were employed as siRNA delivery vectors targeting Ying Yang 1 (YY1) for PCa treatment both in vitro and in vivo. The synergistic antitumor effects of the GUL@LsiYY1@MZ nanosystem were assessed using CCK8 assays, Western blot analysis, flow cytometry, and laser scanning confocal microscopy imaging in vitro. Additionally, the mechanisms underlying the ferroptosis effects were further explored through transcriptome and lipidomics sequencing. Intravenous administration was employed to treat subcutaneous tumors in a mouse model, and the tumor inhibitory effects, safety, and visibility on T<sub>2</sub>-weighted MRI were evaluated.</p> Results <p>The engineered GUL@LsiYY1@MZ nanosystem exploits the specific binding affinity of GUL for the prostate membrane-specific antigen (PSMA), facilitating targeted delivery and accumulation. Upon exposure to alternating magnetic fields (AMF), this system enables the precision-controlled release of siRNA into the cell, leading to the knockdown of YY1 expression. This downregulation subsequently affects the expression of the SLC7A11, thereby disrupting glutathione metabolism. Additionally, the introduction of excess Fe<sup>2+</sup> induces iron overload, further promoting ferroptosis. Significantly, this therapeutic intervention restructured the metabolism of PCa cells, leading to a substantial intracellular accumulation of unsaturated fatty acids. This accumulation provided an abundant substrate for the generation of phospholipid peroxides, ultimately compromising plasma membrane integrity and inducing ferroptosis in PCa cells. Furthermore, the nanosystem also functions as a contrast agent, enhancing the T<sub>2</sub>-weighted MRI imaging of solid tumors.</p> Conclusion <p>The GUL@LsiYY1@MZ nanosystem utilizes AMF-triggered release to downregulate SLC7A11, inducing ferroptosis and contributing to enhanced anti-tumor efficacy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PSMA-targeted theranostic nanoplatform achieves spatiotemporally precise therapy and triggers ferroptosis in prostate cancer treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Linxue Zhang,
  • Qi Sun,
  • Dongxin Zheng,
  • Xiang Huang,
  • Zhong Yu,
  • Zhongwen Lan,
  • Wei Xiong,
  • Ke Sun,
  • Ruiji Liu

摘要

Background

Ferroptosis, an iron-dependent form of regulated cell death, is crucial for the fate of tumors such as prostate cancer (PCa) under conditions of metabolic and oxidative stress. Consequently, the disruption of ferroptosis defense mechanisms could be lethal to these cancer cells, while sparing normal cells. Despite this potential, the development of effective and controlled in vivo therapies targeting ferroptosis remains underexplored.

Methods

In this study, liposomes modified with Glu-urea-Lys (GUL) encapsulating Mn0.6Zn0.4Fe2O4 (MZ) were employed as siRNA delivery vectors targeting Ying Yang 1 (YY1) for PCa treatment both in vitro and in vivo. The synergistic antitumor effects of the GUL@LsiYY1@MZ nanosystem were assessed using CCK8 assays, Western blot analysis, flow cytometry, and laser scanning confocal microscopy imaging in vitro. Additionally, the mechanisms underlying the ferroptosis effects were further explored through transcriptome and lipidomics sequencing. Intravenous administration was employed to treat subcutaneous tumors in a mouse model, and the tumor inhibitory effects, safety, and visibility on T2-weighted MRI were evaluated.

Results

The engineered GUL@LsiYY1@MZ nanosystem exploits the specific binding affinity of GUL for the prostate membrane-specific antigen (PSMA), facilitating targeted delivery and accumulation. Upon exposure to alternating magnetic fields (AMF), this system enables the precision-controlled release of siRNA into the cell, leading to the knockdown of YY1 expression. This downregulation subsequently affects the expression of the SLC7A11, thereby disrupting glutathione metabolism. Additionally, the introduction of excess Fe2+ induces iron overload, further promoting ferroptosis. Significantly, this therapeutic intervention restructured the metabolism of PCa cells, leading to a substantial intracellular accumulation of unsaturated fatty acids. This accumulation provided an abundant substrate for the generation of phospholipid peroxides, ultimately compromising plasma membrane integrity and inducing ferroptosis in PCa cells. Furthermore, the nanosystem also functions as a contrast agent, enhancing the T2-weighted MRI imaging of solid tumors.

Conclusion

The GUL@LsiYY1@MZ nanosystem utilizes AMF-triggered release to downregulate SLC7A11, inducing ferroptosis and contributing to enhanced anti-tumor efficacy.

Graphical abstract